SCHEMBL5547852

SCHEMBL5547852

FC(F)(F)c1ccc(C=C2CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
MAPT P10636 1/20 0.61
MAPK1 P28482 1/20 0.61
BCHE P06276 4/20 0.58
ACHE P22303 4/20 0.58
BACE1 P56817 4/20 0.58
HIF1A Q16665 2/20 0.52
EPAS1 Q99814 2/20 0.52
SIGMAR1 Q99720 4/20 0.52
DRD2 P14416 1/20 0.52
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52
HTR2B P41595 1/20 0.52
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
POLB P06746 1/20 0.50
GAA P10253 1/20 0.50
MCHR1 Q99705 1/20 0.49
HRH3 Q9Y5N1 1/20 0.49
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2257602 0.85 SIGMAR1 (0.59) LMNAACHEBACE1SIGMAR1ALDH1A1
SCHEMBL5817187 0.84 ACHE (0.56) BCHEACHEBACE1SIGMAR1DRD2
SCHEMBL5535158 0.84 BCHE (0.62) BCHEACHEBACE1SIGMAR1DRD2
SCHEMBL2514685 0.78 HRH3 (0.52) MAPK1ACHEHIF1ASIGMAR1DRD2
SCHEMBL3168599 0.78 SIGMAR1 (0.66) LMNAMAPTMAPK1ACHEBACE1
SCHEMBL6071351 0.76 MCHR1 (0.58) ALDH1A1GAAMCHR1HRH3
SCHEMBL3149156 0.76 MCHR1 (0.53) MAPK1SIGMAR1MCHR1HRH3
SCHEMBL5888769 0.75 ALDH1A1 (0.50) MAPK1ACHEBACE1SIGMAR1ALDH1A1
SCHEMBL12274508 0.75 RORC (0.47) LMNAMAPTMAPK1HIF1AEPAS1
SCHEMBL14013779 0.72 HRH3 (0.52) LMNAMAPK1ACHEBACE1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-102532162-A 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2012-07-04 CN disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LMNA 4152/4885MAPT 4117/4885MAPK1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.